Litcius/Paper detail

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials

Mikhail Kosiborod, John Deanfield, Richard Pratley, Barry A. Borlaug, Javed Butler, Melanie J. Davies, Scott S. Emerson, Steven E. Kahn, Dalane W. Kitzman, Ildiko Lingvay, Kenneth W. Mahaffey, Mark C. Petrie, Jorge Plutzky, Søren Rasmussen, Cecilia Rönnbäck, Sanjiv J. Shah, Subodh Verma, Peter Weeke, A. Michael Lincoff

2024The Lancet267 citationsDOI

Topics & Concepts

SemaglutideHeart failure with preserved ejection fractionMedicineHeart failureCardiologyInternal medicineEjection fractionPlaceboOverweightType 2 diabetesDiabetes mellitusObesityEndocrinologyLiraglutidePathologyAlternative medicineDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsHeart Failure Treatment and Management
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials | Litcius